Form 4 Filing for Arcutis Biotherapeutics, Inc.

This filing details stock transactions by Terrie Curran, a director at Arcutis Biotherapeutics, Inc. On June 5, 2026, Curran acquired 5,778 shares of Common Stock and was granted an option to buy 16,667 shares of Common Stock. The shares acquired are part of Restricted Stock Units (RSUs) granted in connection with Curran's service as a non-employee director, vesting on the earlier of the first anniversary of the grant date or immediately before the next annual meeting, subject to continued service. The settlement of these RSUs has been deferred. The stock option also vests under similar conditions. Curran has deferred the settlement of RSUs, and the stock option vests under specific conditions related to continued service.